Ichnos Sciences, a wholly-owned subsidiary of Glenmark Pharmaceuticals, is a leading global biotechnology company specialising in innovative multispecific antibodies for oncology, has recently unveiled an exclusive worldwide licensing agreement. This agreement with Astria Therapeutics, a biopharmaceutical company dedicated to developing therapies for rare allergic and immunological diseases, marks a pivotal moment in Ichnos’s commitment to …


